Plain-English translation of NCT05372354 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called in combination with other cancer treatments for people with multiple myeloma that has returned or stopped responding to previous therapies. Researchers want to find the safest and most effective dose of this medication and understand how well it works when paired with other drugs. The study will help doctors learn whether this new combination approach might offer hope for patients who have limited treatment options left.
Multiple myeloma is a blood cancer, and some patients develop resistance to standard treatments or their cancer comes back after therapy. This trial exists because doctors need new options for these patients and believe that combining this medication with other drugs might work better than single treatments alone.
You likely qualify if…
You likely don't qualify if…
Participants in this trial will take the new medication along with other cancer drugs as part of their treatment regimen. The study has two main phases: first, researchers will test different doses to find the safest amount (Dose Finding), and then they will enroll more patients at the best dose to confirm how well it works (Dose Expansion). You would attend regular clinic visits for blood work, health checks, and to receive your medication; the exact schedule depends on which part of the study you join.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
United States